Körber and Immunotech Biopharm will implement Werum PAS-X MES in a greenfield cell & gene site in Beijing. This step is an important milestone to start Immunotech’s digital journey towards intelligent manufacturing.

As the China domestic leader in cell & gene therapy, Immunotech regards digitization and intelligent manufacturing as one of the company’s core strategies. By introducing Körber’s Manufacturing Execution System (MES) Werum PAS-X in the greenfield site in Beijing, Immunotech will build a new smart factory that takes into account safety and efficiency, while enabling interconnection and data transfer during the entire production process. In this way, the company can accelerate the strategic process of digitization and intelligence, and provide more high-quality products and services to the market.

“We are very pleased to reach a comprehensive cooperation with Körber,” says Dr. Wang Yu, Chief Executive Officer (CEO) of Immunotech Biopharm Ltd. “As the market leader, Werum PAS-X MES has unique advantages, which offers us innovative concepts and industry best practices. PAS-X combines software, content and services, and ensures fast deployment. I am looking forward to our joint cooperation, laying a solid foundation for Immunotech to accelerate product commercialization as well as to provide strong technical support to achieve our ultimate goal of curing patients.”

Jerry Zheng, General Manager China Hub of Körber Business Area Pharma, adds: “Against the backdrop of Industry 4.0, the strategic plan ‘Made in China 2025’ and the integration of digitization and intelligence in various industries across China, leveraging technology to assist the pharmaceutical industry is the trend of the future. Our PAS-X software solution has always been focusing on the factory and supply chain, while taking into account the specific requirements of the regulatory agencies and the industry itself. MES is an important entry point and breakthrough to drive intelligent manufacturing, and it is an important vehicle for the digital transformation of pharmaceutical companies.”